Trials / Completed
CompletedNCT02640222
APIXABAN in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France SNIIRAM Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 321,501 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the APIXABAN use in the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation in Real-Life Setting in France, data from SNIIRAM (French data base).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VKA | |
| DRUG | Apixaban | |
| DRUG | dabigatran | |
| DRUG | rivaroxaban |
Timeline
- Start date
- 2014-01-01
- Primary completion
- 2016-12-31
- Completion
- 2019-12-31
- First posted
- 2015-12-28
- Last updated
- 2022-05-18
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT02640222. Inclusion in this directory is not an endorsement.